Taiwan · Delayed Price · Currency is TWD Taho Pharmaceuticals Company Description
Taho Pharmaceuticals Ltd., a pharmaceutical company, develops products using transdermal and transmucosal systems in Taiwan.
The company’s portfolio includes TAH4411 Ondansetron ODF for the treatment of chemotherapy-induced nausea and vomiting; TAH3311 apixaban oral film, which is in phase 3 clinical trial for patients with Dysphagia; TAH3341 apixaban oral extend release film for patients with Dysphagia; TAH2211 Buprenorphine/Naloxone sublingual film, which is in phase 1 clinical trial for opioid addiction; TAH2231 Naloxone Buccal film , which is in phase 1 clinical trial for opioid overdose; TAH9922 atomoxetine oral liquid, which is in phase 1 clinical trial; and TAH9901 methylphenidate patch, which is in phase 1 clinical trial for the treatment of deficit and hyperactivity disorder.
The company was founded in 2010 and is based in Taipei, Taiwan.
| Country | Taiwan |
| Founded | 2010 |
| Industry | Pharmaceutical Preparations |
| Employees | 27 |
| CEO | Shiren S. Lee |
Contact Details
Address: No.550, Ruiguang Road Taipei, 11492 Taiwan | |
| Phone | 886 2 2659 8515 |
| Website | tahopharma.com |
Stock Details
| Ticker Symbol | 6467 |
| Exchange | Taipei Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Shiren S. Lee | Chief Executive Officer |
| Yu Zhang | Chief Financial Officer |